The estimated Net Worth of P Roy Vagelos is at least $581 Millón dollars as of 22 February 2023. P Vagelos owns over 42,500 units of Regeneron Pharmaceuticals stock worth over $418,436,165 and over the last 21 years he sold REGN stock worth over $140,166,003. In addition, he makes $22,304,300 as Chairman of the Board y Director at Regeneron Pharmaceuticals.
P has made over 50 trades of the Regeneron Pharmaceuticals stock since 2007, according to the Form 4 filled with the SEC. Most recently he exercised 42,500 units of REGN stock worth $11,493,275 on 22 February 2023.
The largest trade he's ever made was exercising 312,500 units of Regeneron Pharmaceuticals stock on 20 May 2020 worth over $9,571,875. On average, P trades about 53,056 units every 66 days since 2003. As of 22 February 2023 he still owns at least 366,583 units of Regeneron Pharmaceuticals stock.
You can see the complete history of P Vagelos stock trades at the bottom of the page.
Dr. P. Roy Vagelos M.D. serves as Chairman of the Board, Director of the Company. Prior to joining Regeneron, Dr. Vagelos was Chairman of the Board and Chief Executive Officer of Merck & Co., Inc., a global pharmaceutical company. He joined Merck in 1975, became a director in 1984, President and Chief Executive Officer in 1985, and Chairman in 1986. Dr. Vagelos retired from all positions with Merck in 1994. Dr. Vagelos served on the board of directors of Theravance, Inc. from 1996 to 2010. Dr. Vagelos is a member of the National Academy of Sciences, the National Academy of Medicine, and the American Philosophical Society. During his tenure as Chairman of Regeneron and previously as Chairman and Chief Executive Officer of Merck, Dr. Vagelos developed an extensive understanding of the complex business, operational, scientific, regulatory, and commercial issues facing the pharmaceutical industry. Dr. Vagelos’s tenure and experience with the Company and Merck, his extensive knowledge of the pharmaceutical industry, his substantial leadership experience, and his significant understanding of the Company led to the board’s decision to nominate Dr. Vagelos for reelection to the board.
As the Chairman of the Board y Director of Regeneron Pharmaceuticals, the total compensation of P Vagelos at Regeneron Pharmaceuticals is $22,304,300. There are no executives at Regeneron Pharmaceuticals getting paid more.
P Vagelos is 90, he's been the Chairman of the Board y Director of Regeneron Pharmaceuticals since 1995. There are no older and 24 younger executives at Regeneron Pharmaceuticals.
Over the last 22 years, insiders at Regeneron Pharmaceuticals have traded over $13,084,686,326 worth of Regeneron Pharmaceuticals stock and bought 8,562,481 units worth $2,539,854,760 . The most active insiders traders include Sanofi, Pharma Ag Novartis y Leonard S Schleifer. On average, Regeneron Pharmaceuticals executives and independent directors trade stock every 8 days with the average trade being worth of $47,694,347. The most recent stock trade was executed by Marion Mc Court on 3 September 2024, trading 1,000 units of REGN stock currently worth $381,400.
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988.
Regeneron Pharmaceuticals executives and other stock owners filed with the SEC include: